CELLMEMBRANE: Development of delignified nanocellulose based gas transfer scaffold membrane for artificial lung applications

CELLMEMBRANE：开发用于人工肺应用的脱木质素纳米纤维素基气体传输支架膜

• 批准号: 10093284
• 金额: $ 50.61万
• 依托单位: BRUNEL UNIVERSITY LONDON
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10093284
• 关键词: CELLMEMBRANE; Development; delignified; nanocellulose; based

Lung disease is the third biggest cause of deaths globally. For the irreversible and terminal lung disease patients, lung transplantation is the only long-term therapy. Due to the unavailability the suitable donors, there is not only a minimum of 18 months of wait on the organ donation. Patients who eventually secure a lung transplant have lessthan 20% chance of recovery due to ‘poor organ function’. Therefore, there is not only a great need for an artificial lung as a permanent replacement organ but also as a bridge to transplantation. Existing artificial lung devices fail to mimic the flow gas exchange properties of a human lung and suffer from low biocompatibility, leading to undesired blood coagulation and hemolysis which limits their applicability to up to 30 days. The complexity and risk associated with current artificial lung technologies mean that they are not offered aslong-term lung replacements or as a suitable bridge to transplantation. Through this 36 months EIC pathfinder project, the consortium led by Smart Reactors Ireland, aims to develop the world’s first biobased nanomaterial ‘nanocellulose’ to manufacture an artificial lung device used as a bridge to lung transplantation. The consortium will develop an initial proof of concept nanocellulose device to demonstrate gas transfer and initial hemocompatibility in blood. The proposed approach is expected to have two benefits, the first is that blood flow can occur in laminar flow conditions reducing haemolysis and damage to the blood. Secondly, nanocellulose, has the potential to be endothelialized which would allow for long term gas exchange without the need for systemic anticoagulants.

肺部病是全球死亡的第三大原因。对于不可逆和终末肺部疾病患者，肺移植是唯一的长期治疗。由于不可用的捐赠者，不仅可以在器官捐赠上等待18个月。由于“器官功能差”，有时获得肺移植的患者的恢复可能性较小。因此，不仅需要人造肺作为永久替代器官，而且还需要作为移植的桥梁。现有的人工肺部装置无法模仿人类肺的流量交换特性，并且生物相容性低，导致不良的血液凝结和溶血，从而将其适用性限制在30天内。与当前人工肺技术相关的复杂性和风险意味着未提供垂直肺部替代品或作为合适的移植桥。在这个36个月的EIC Pathfinder项目中，由智能反应堆的爱尔兰领导的财团旨在开发世界上第一个基于生物的纳米材料“纳米纤维素”，以制造一种人工肺部装置，用作肺部移植的桥梁。该财团将开发概念纳米纤维素装置的初始证明，以证明血液中的气体转移和初始的失血性。预计所提出的方法将具有两个好处，首先是在层流条件下可能发生血流，从而减少溶血和血液损害。其次，纳米纤维素具有内皮化的潜力，这将允许长期的气体交换而无需全身性抗凝剂。